FASN and ovarian carcinoma: In our study, we have explored the use of the FASN inhibitor orlistat as a way of overcoming resistance to cisplatin in cisplatin‐refractory ovarian cancer and examined their effects as monotherapies or as a combination, on tumour metabolism.